Avantor(US:AVTR) Prnewswire·2025-11-07 22:55Core Viewpoint - Avantor, Inc. is facing a class action lawsuit due to allegations of misleading investors about the impact of increased competition on its financial performance [1][2]. Summary by Sections Company Overview - Avantor, Inc. (NYSE: AVTR) provides scientific products and services across various sectors including biotechnology, pharmaceuticals, healthcare, education, and government [1]. Allegations - The lawsuit claims that Avantor's management failed to disclose the following: 1. The company's competitive positioning was weaker than publicly represented 2. Avantor was negatively affected by increased competition 3. The representations made about the company's business, operations, and prospects were materially false and misleading [2]. Financial Performance - On October 29, 2025, Avantor reported disappointing third-quarter results, including: - A -5% organic revenue growth, which was below the guidance provided in August - A net loss of $712 million, primarily due to a non-cash goodwill impairment charge of $785 million - The impairment charge was attributed to "competitive pressures" that significantly impacted the company's margins and the loss of several large accounts - Following this announcement, Avantor's stock price fell by $3.50 per share, a decline of over 23%, from $15.08 on October 28, 2025, to $11.58 on October 29, 2025 [3].